Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System [Yahoo! Finance]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Yahoo! Finance
NEWARK, Calif., March 17, 2025 BUSINESS WIRE Corsair Pharma, Inc. , a private biopharmaceutical company, today announced the successful completion of the preclinical program of its TRX-248 Transdermal System, a once-daily transdermal patch for the treatment of Pulmonary Arterial Hypertension (PAH). These positive results support the initiation of a Phase 1 human trial expected to begin in the second quarter of 2025. Prostacyclins are the standard of care drug class to treat PAH. The Corsair transdermal patch is intended to provide steady and continuous blood levels of the prostacyclin drug treprostinil. The patch, applied once daily, delivers an inactive prodrug (TRX-248), which crosses the skin, enters the blood and converts rapidly to treprostinil in the liver. Corsair also believes that the patch has the potential to treat other forms of pulmonary hypertension. "Across several studies in minipigs, the transdermal formulations of the proprietary prodrug were optimized to demons
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base [Yahoo! Finance]Yahoo! Finance
- United Therapeutics: Growing Company With Great Franchise In Pulmonary Diseases [Seeking Alpha]Seeking Alpha
- United Therapeutics (NASDAQ:UTHR) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- United Therapeutics (NASDAQ:UTHR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 12/22/25 - Form 144
- 12/19/25 - Form 144
- 12/19/25 - Form 4
- UTHR's page on the SEC website